Major Overhang for ImmunoCellular (IMUC) Removed with CIRM Grant - Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
ImmunoCellular Therapeutics (IMUC) Announces $19.9M Award from CIRM to Fund ICT-107 Phase 3 in Glioblastoma
September 24, 2015 1:54 PM EDTImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $19.9 million to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma. The $19.9 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107... More
